Yu H, Cai J J, Lee H C
Department of Internal Medicine, University of Iowa College of Medicine, Iowa City 52242, USA.
Mol Pharmacol. 1996 Sep;50(3):549-55.
We recently reported that protein kinase C (PKC) potentiates cAMP-dependent phosphodiesterase (PDE) activity in Syrian hamster hearts with hypertrophic cardiomyopathy (HCM) but not in control hamster hearts. In this study, we examined the mechanism of this PKC/PDE interaction by identifying the PDE isozyme that is the target of PKC modulation. Using Mono-Q high performance liquid chromatography, both control and HCM hamster cardiac PDE could be partially purified into the calcium/calmodulin-dependent (I), the cGMP-stimulated (II), and the low KM (III) isozyme fractions. The elution profiles of PDE isozyme fractions were similar to those in isolated hamster cardiac myocytes. The percentages of PDE isozymes activities (I/II/III) were 68.8:22.4:8.8% and 51.1:38.4:10.5% for HCM and control hearts, respectively (n = 4), suggesting a change in the quantitative expression of isozymes activities in HCM hearts with a significant increase in the calcium/calmodulin-dependent PDE isozyme activities (p < 0.05 compared with control). The addition of exogenous PKC (100 munits of rat brain) produced a 60% stimulation in the calcium/calmodulin-dependent PDE isozyme fraction but not in other PDE isozymes of HCM and in none of the isozymes in control hearts. This PKC-mediated potentiation of the calcium/calmodulin-dependent PDE activity was completely blocked by the PKC-specific peptide inhibitor PKC(19-31). Analysis of enzymatic kinetics showed that PKC enhanced the calcium/calmodulin-dependent PDE isozyme activity in HCM by increasing its Vmax (from 350 pmol/mg/min at baseline to 758 pmol/min/mg with PKC) without changing its KM (0.69 microM at baseline versus 0.89 microM with PKC). These results suggest that there are both quantitative and qualitative abnormalities in the expression of the calcium/ calmodulin-dependent PDE isozyme in HCM hearts and that the PKC modulation of PDE activity in the HCM heart is isozyme specific.
我们最近报道,蛋白激酶C(PKC)可增强患有肥厚型心肌病(HCM)的叙利亚仓鼠心脏中cAMP依赖性磷酸二酯酶(PDE)的活性,但对对照仓鼠心脏则无此作用。在本研究中,我们通过鉴定作为PKC调节靶点的PDE同工酶来研究这种PKC/PDE相互作用的机制。使用Mono-Q高效液相色谱法,对照和HCM仓鼠心脏的PDE均可部分纯化至钙/钙调蛋白依赖性(I)、cGMP刺激型(II)和低KM(III)同工酶组分。PDE同工酶组分的洗脱曲线与分离的仓鼠心肌细胞中的相似。HCM和对照心脏中PDE同工酶活性(I/II/III)的百分比分别为68.8:22.4:8.8%和51.1:38.4:10.5%(n = 4),这表明HCM心脏中同工酶活性的定量表达发生了变化,钙/钙调蛋白依赖性PDE同工酶活性显著增加(与对照相比,p < 0.05)。添加外源性PKC(100单位大鼠脑)可使HCM的钙/钙调蛋白依赖性PDE同工酶组分活性增强60%,但对HCM的其他PDE同工酶以及对照心脏的任何同工酶均无作用。PKC介导的钙/钙调蛋白依赖性PDE活性增强被PKC特异性肽抑制剂PKC(19 - 31)完全阻断。酶动力学分析表明,PKC通过增加HCM中钙/钙调蛋白依赖性PDE同工酶的Vmax(从基线时的350 pmol/mg/min增加到PKC存在时的758 pmol/min/mg)而不改变其KM(基线时为0.69 microM,PKC存在时为0.89 microM)来增强其活性。这些结果表明,HCM心脏中钙/钙调蛋白依赖性PDE同工酶的表达在数量和质量上均存在异常,并且HCM心脏中PKC对PDE活性的调节具有同工酶特异性。